Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 12NIH 8INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Multiple Myeloma 161Recurrence 30Neoplasms, Plasma Cell 11Neoplasms 7Lymphoma, Mantle-Cell 7Paraproteinemias 6Lymphoma, Follicular 5Hematologic Neoplasms 5Lymphoma, Non-Hodgkin 4Immunoglobulin Light-chain Amyloidosis 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Diseases 3Carcinoma, Non-Small-Cell Lung 3Blood Protein Disorders 3Plasmacytoma 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Lymphoproliferative Disorders 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Hemostatic Disorders 2Hemorrhagic Disorders 2Bone Marrow Neoplasms 2Amyloidosis 2Wilms Tumor 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × Bortezomib × Clear all
NCT00117351 2011-02-17

VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

Millennium Pharmaceuticals, Inc.

Phase 2 Terminated
Thoracic

Adenocarcinoma, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00051974 2008-02-11

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
155 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡